Targeting ERK combined with apatinib may be a promising therapeutic strategy for treating oral squamous cell carcinoma

Zhao, TC; Liang, SY; Zhou, ZH; Ju, WT; Zhang, ZY; Zhu, DW; Zhong, LP

Zhu, DW; Zhong, LP (corresponding author), Shanghai Jiao Tong Univ, Dept Oral & Maxillofacial Head & Neck Oncol, Sch Med, Peoples Hosp 9,Coll Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.

AMERICAN JOURNAL OF CANCER RESEARCH, 2021; 11 (6): 2960

Abstract

Apatinib is an oral tyrosine kinase inhibitor that targets VEGFR2 signaling and shows potent antitumor effects in various cancers. In this study, we e......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索